Tweets by SSO 2024 Annual Meeting

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Recorded for On-Demand Viewing

Back

Management of Mid-Rectal Cancer

Mismatch-repair Deficient Cancers

Saturday, March 23, 2024

11:30am – 11:40am ET

Location: C102

Presenter(s)

Olatunji Alese, MD

Associate Professor
Winship Cancer Institute of Emory University

Disclosure(s):

Olatunji Alese, MD: Aadi Bioscience: Advisor (Terminated); AstraZeneca: Advisor (Terminated); Bristol Myers Squibb: Advisor (Ongoing), Contracted Research (Ongoing); Compass Therapeutics, Inc.: Advisor (Ongoing); Exelixis: Advisor (Terminated); GSK: Advisor (Ongoing), Contracted Research (Ongoing); Ipsen Pharmaceuticals: Advisor (Terminated), Contracted Research (Terminated); Pfizer: Advisor (Ongoing), Contracted Research (Ongoing); Seagen Inc.: Advisor (Ongoing), Contracted Research (Ongoing); Taiho: Advisor (Ongoing), Contracted Research (Ongoing); Takeda : Advisor (Terminated)

Rapid advances in the field of rectal cancer along with changing patient demographics make the management of the mid-rectal tumor challenging. This session will review the results of the OPRA and PROSPECT trials, the treatment of mismatch-repair-deficient cancers, and special considerations for young adults and patients with inflammatory bowel disease.